PROCEPT BioRobotics (NASDAQ:PRCT) Given New $34.00 Price Target at TD Cowen

PROCEPT BioRobotics (NASDAQ:PRCT) had its price target decreased by TD Cowen from $50.00 to $34.00 in a report released on Thursday, Marketbeat reports. TD Cowen currently has a buy rating on the stock.

A number of other analysts have also commented on the company. Leerink Partners reaffirmed an “outperform” rating and issued a $55.00 target price on shares of PROCEPT BioRobotics in a research report on Wednesday, November 5th. Wall Street Zen upgraded shares of PROCEPT BioRobotics from a “sell” rating to a “hold” rating in a report on Saturday, January 10th. Jefferies Financial Group upgraded PROCEPT BioRobotics from a “hold” rating to a “strong-buy” rating in a report on Friday, December 12th. Wells Fargo & Company dropped their target price on shares of PROCEPT BioRobotics from $51.00 to $34.00 and set an “overweight” rating on the stock in a research note on Thursday. Finally, Piper Sandler dropped their price target on PROCEPT BioRobotics from $50.00 to $28.00 and set an “overweight” rating on the stock in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.60.

PROCEPT BioRobotics Price Performance

Shares of NASDAQ PRCT opened at $23.63 on Thursday. The firm has a fifty day simple moving average of $30.18 and a 200 day simple moving average of $33.64. PROCEPT BioRobotics has a twelve month low of $19.35 and a twelve month high of $68.70. The company has a quick ratio of 7.20, a current ratio of 8.44 and a debt-to-equity ratio of 0.14. The company has a market capitalization of $1.32 billion, a PE ratio of -13.82 and a beta of 0.99.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its earnings results on Wednesday, February 25th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.21). PROCEPT BioRobotics had a negative net margin of 31.02% and a negative return on equity of 24.82%. The business had revenue of $76.38 million for the quarter, compared to the consensus estimate of $93.70 million. During the same quarter in the previous year, the company earned ($0.35) EPS. The firm’s revenue for the quarter was up 11.9% on a year-over-year basis. On average, sell-side analysts forecast that PROCEPT BioRobotics will post -1.75 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in PRCT. Alliancebernstein L.P. boosted its holdings in shares of PROCEPT BioRobotics by 58.6% in the 3rd quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company’s stock worth $122,052,000 after purchasing an additional 1,262,928 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its position in PROCEPT BioRobotics by 59.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company’s stock valued at $102,919,000 after buying an additional 1,218,815 shares during the period. Westfield Capital Management Co. LP grew its holdings in PROCEPT BioRobotics by 23.3% in the 3rd quarter. Westfield Capital Management Co. LP now owns 1,970,147 shares of the company’s stock worth $70,315,000 after acquiring an additional 371,798 shares during the last quarter. Mackenzie Financial Corp increased its position in shares of PROCEPT BioRobotics by 8.2% in the fourth quarter. Mackenzie Financial Corp now owns 1,573,405 shares of the company’s stock valued at $49,512,000 after acquiring an additional 118,971 shares during the period. Finally, Chicago Capital LLC raised its stake in shares of PROCEPT BioRobotics by 175.7% during the third quarter. Chicago Capital LLC now owns 1,568,845 shares of the company’s stock valued at $55,992,000 after acquiring an additional 999,873 shares during the last quarter. Institutional investors own 89.46% of the company’s stock.

PROCEPT BioRobotics News Summary

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Solid cash runway and improving operating losses — Q4 showed an improved operating loss and the company ended the quarter with roughly $286.5M in cash and total liabilities of $142.2M, which supports near‑term execution. Quiver Quant Earnings Summary
• Positive Sentiment: FY‑2026 revenue guidance range ($390M–$410M) was raised/updated and sits near analyst consensus, giving some multi‑quarter visibility for modeling. Q4 Results & Guidance (GlobeNewswire)
• Neutral Sentiment: Company hosted an Investor Day outlining its multi‑year plan — strategic detail may help longer‑term sentiment but did not offset near‑term headline risk. Investor Day Release
• Negative Sentiment: Earnings and revenue misses — Q4 revenue of ~$76.4M (+11.9% YoY) and diluted loss of $0.53 missed consensus (revenue and EPS), and Q1 revenue guidance ($79M–$82M) came in well below street expectations — the primary catalyst for selling. Q4 Results & Guidance (GlobeNewswire)
• Negative Sentiment: New securities‑fraud investigation announced by law firm Ademi LLP, alleging possible inaccurate statements about financials/operations — this raises regulatory/legal overhang and investor risk. Ademi LLP Investigation
• Negative Sentiment: Multiple analyst price‑target cuts and a Bank of America downgrade to underperform (PT $20) plus cuts from Leerink, TD Cowen and Piper Sandler increased selling pressure; some firms remain constructive but consensus risk has risen. Analyst Coverage/Benzinga TD Cowen Comment
• Negative Sentiment: Heavy institutional selling and a spike in volume pushed the stock to a 52‑week low; hedge‑fund and mutual‑fund position reductions magnified the decline. Quiver Quant (institutional moves) Benzinga: 52‑Week Low

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.